Browse by People

Collapse authors list.
Burnett, Alan K, Das Gupta, Emma, Knapper, Steve, Khwaja, Asim, Sweeney, Marion, Kjeldsen, Lars, Hawkins, Timothy, Betteridge, Sophie E, Cahalin, Paul, Clark, Richard E ORCID: 0000-0002-1261-3299 et al (show 2 more authors) , Hills, Robert K and Russel, Nigel H (2018) Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. HAEMATOLOGICA, 103 (10). pp. 1654-1661.

Clark, Richard E ORCID: 0000-0002-1261-3299, Apperley, Jane F, Copland, Mhairi and Cicconi, Silvia (2021) Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. BLOOD ADVANCES, 5 (4). pp. 1102-1109.

Collapse authors list.
Brummendorf, Tim H, Cortes, Jorge E, Milojkovic, Dragana, Gambacorti-Passerini, Carlo, Clark, Richard E ORCID: 0000-0002-1261-3299, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Chuah, Charles, Kota, Vamsi, Lipton, Jeffrey H et al (show 9 more authors) , Rousselot, Philippe, Mauro, Michael J, Hochhaus, Andreas, Hurtado Monroy, Rafael, Leip, Eric, Purcell, Simon, Yver, Anne, Viqueira, Andrea and Deininger, Michael W (2022) Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. , England.

Collapse authors list.
Kinstrie, Ross, Horne, Gillian A, Morrison, Heather, Irvine, David, Munje, Chinmay, Castaneda, Eduardo Gomez, Moka, Hothri A, Dunn, Karen, Cassels, Jennifer E, Parry, Narissa et al (show 6 more authors) , Clarke, Cassie J, Scott, Mary T, Clark, Richard E ORCID: 0000-0002-1261-3299, Holyoake, Tessa L, Wheadon, Helen and Copland, Mhairi (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. LEUKEMIA, 34 (6). pp. 1613-1625.

Lucas, Claire M ORCID: 0000-0001-6674-7535, Scott, Laura J, Carmell, Natasha, Holcroft, Alison K, Hills, Robert K, Burnett, Alan K and Clark, Richard E ORCID: 0000-0002-1261-3299 (2018) CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Advances, 2 (9). pp. 964-968.

Austin, James A, Jenkins, Rosalind E, Austin, Gemma M, Glenn, Mark A, Dunn, Karen, Scott, Laura, Lucas, Claire M ORCID: 0000-0001-6674-7535 and Clark, Richard E ORCID: 0000-0002-1261-3299 (2019) Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5′ AMP-activated protein kinase signalling in malignant cells. BIOCHEMICAL JOURNAL, 476 (15). pp. 2255-2269.

Collapse authors list.
Clark, Richard E ORCID: 0000-0002-1261-3299, Polydoros, Fotios ORCID: 0000-0001-5181-6817, Apperley, Jane F, Milojkovic, Dragana, Pocock, Christopher, Smith, Graeme, Byrne, Jenny L, de lavallade, Hugues, O'Brien, Stephen G, Coffey, Tony et al (show 2 more authors) , Foroni, Letizia and Copland, Mhairi (2017) De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. The Lancet Haematology, 4 (7). E310-E316.

Collapse authors list.
Clark, Richard E ORCID: 0000-0002-1261-3299, Polydoros, Fotios, Apperley, Jane F, Milojkovic, Dragana, Rothwell, Katherine, Pocock, Christopher, Byrne, Jennifer, de lavallade, Hugues, Osborne, Wendy, Robinson, Lisa et al (show 4 more authors) , O'Brien, Stephen G, Read, Lucy, Foroni, Letizia and Copland, Mhairi (2019) De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. The Lancet Haematology, 6 (7). E375-E383.

Collapse authors list.
Burnett, Alan K, Russell, Nigel H, Hills, Robert K, Knapper, Stephen, Freeman, Sylvie, Huntly, Brian, Clark, Richard E ORCID: 0000-0002-1261-3299, Thomas, Ian F, Kjeldsen, Lars, McMullin, Mary Frances et al (show 3 more authors) , Drummond, Mark, Kell, Jonathan and Spearing, Ruth (2020) Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39 (8). JCO2001170-JCO2001170.

Collapse authors list.
Makela, Eleonora, Pavic, Karolina, Varila, Taru, Salmenniemi, Urpu, Loyttyniemi, Eliisa, Nagelli, Srikar G, Ammunet, Tea, Kahari, Veli-Matti, Clark, Richard E ORCID: 0000-0002-1261-3299, Elo, Laura L et al (show 4 more authors) , Bachanaboyina, Venkata Kumari, Lucas, Claire M, Itala-Remes, Maija and Westermarck, Jukka (2021) Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. CLINICAL CANCER RESEARCH, 27 (10). pp. 2848-2860.

Collapse authors list.
Pfirrmann, Markus, Clark, Richard E ORCID: 0000-0002-1261-3299, Prejzner, Witold, Lauseker, Michael, Baccarani, Michele, Saussele, Susanne, Guilhot, Francois, Heibl, Sonja, Hehlmann, Rudiger, Faber, Edgar et al (show 20 more authors) , Turkina, Anna, Ossenkoppele, Gert, Hoglund, Martin, Zaritskey, Andrey, Griskevicius, Laimonas, Olsson-Stromberg, Ulla, Everaus, Hele, Koskenvesa, Perttu, Labar, Boris, Sacha, Tomasz, Zackova, Daniela, Cervantes, Francisco, Colita, Adriana, Zupan, Irena, Bogdanovic, Andrija, Castagnetti, Fausto, Guilhot, Joelle, Hasford, Joerg, Hochhaus, Andreas and Hoffmann, Verena S (2020) The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. LEUKEMIA, 34 (8). pp. 2138-2149.

Martin, Antony P ORCID: 0000-0003-4383-6038, Richards, Sarah, Haycox, Alan ORCID: 0000-0001-6659-4866, Houten, Rachel ORCID: 0000-0002-4315-7732, McLeod, Claire, Braithwaite, Barbara, Clark, Jack O, Bell, Joanne and Clark, Richard E ORCID: 0000-0002-1261-3299 (2016) Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial. JOURNAL OF CLINICAL APHERESIS, 31 (5). pp. 434-442.

Tidd, David M, Giles, Richard V, Broughton, Caroline M and Clark, Richard E (2001) Expression of c-myc is not critical for cell proliferation in established human leukemia lines. BMC Molecular Biology, 2.

Kinstrie, Ross, Karamitros, Dimitris, Goardon, Nicolas, Morrison, Heather, Hamblin, Mike, Robinson, Lisa, Clark, Richard E ORCID: 0000-0002-1261-3299, Copland, Mhairi and Vyas, Paresh (2016) Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. BLOOD ADVANCES, 1 (3). pp. 160-169.

Collapse authors list.
Kantarjian, Hagop M, Hughes, Timothy P, Larson, Richard A, Kim, Dong-Wook, Issaragrisil, Surapol, le Coutre, Philipp, Etienne, Gabriel, Boquimpani, Carla, Pasquini, Ricardo, Clark, Richard E ORCID: 0000-0002-1261-3299 et al (show 11 more authors) , Dubruille, Viviane, Flinn, Ian W, Kyrcz-Krzemien, Slawomira, Medras, Ewa, Zanichelli, Maria, Bendit, Israel, Cacciatore, Silvia, Titorenko, Ksenia, Aimone, Paola, Saglio, Giuseppe and Hochhaus, Andreas (2021) Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia, 35 (2). pp. 440-453.

Karg, Elena, Baldow, Christoph, Zerjatke, Thomas, Clark, Richard E ORCID: 0000-0002-1261-3299, Roeder, Ingo, Fassoni, Artur C and Glauche, Ingmar (2022) Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation. FRONTIERS IN ONCOLOGY, 12. 1028871-.

Gottschalk, Andrea, Glauche, Ingmar, Cicconi, Silvia ORCID: 0000-0001-5507-6203, Clark, Richard E ORCID: 0000-0002-1261-3299 and Roeder, Ingo (2020) Molecular dynamics during reduction of TKI dose reliably identify molecular recurrence after treatment cessation in CML. Blood, 135 (10). pp. 766-769.

Russell, Nigel H, Hills, Robert K, Thomas, Abin, Thomas, Ian, Kjeldsen, Lars, Dennis, Mike, Craddock, Charles, Freeman, Sylvie, Clark, Richard E ORCID: 0000-0002-1261-3299 and Burnett, Alan K (2022) Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. HAEMATOLOGICA, 107 (7). pp. 1518-1527.

Collapse authors list.
Copland, Mhairi, Slade, Daniel, McIlroy, Graham, Horne, Gillian, Byrne, Jenny L, Rothwell, Kate, Brock, Kristian, De Lavallade, Hugues, Craddock, Charles, Clark, Richard E ORCID: 0000-0002-1261-3299 et al (show 5 more authors) , Smith, Matthew L, Fletcher, Rachel, Bishop, Rebecca, Milojkovic, Dragana and Yap, Christina (2022) Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. LANCET HAEMATOLOGY, 9 (2). E121-E132.

Collapse authors list.
Lauseker, Michael, Bachl, Katharina, Turkina, Anna, Faber, Edgar, Prejzner, Witold, Olsson-Stromberg, Ulla, Baccarani, Michele, Lomaia, Elza, Zackova, Daniela, Ossenkoppele, Gert et al (show 12 more authors) , Griskevicius, Laimonas, Schubert-Fritschle, Gabriele, Sacha, Tomasz, Heibl, Sonja, Koskenvesa, Perttu, Bogdanovic, Andrija, Clark, Richard E ORCID: 0000-0002-1261-3299, Guilhot, Joelle, Hoffmann, Verena S, Hasford, Joerg, Hochhaus, Andreas and Pfirrmann, Markus (2019) Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. AMERICAN JOURNAL OF HEMATOLOGY, 94 (11). pp. 1236-1243.

Collapse authors list.
Dennis, Mike, Thomas, Ian F, Ariti, Cono, Upton, Laura, Burnett, Alan K, Gilkes, Amanda, Radia, Rohini, Hemmaway, Claire, Mehta, Priyanka, Knapper, Steven et al (show 5 more authors) , Clark, Richard E ORCID: 0000-0002-1261-3299, Copland, Mhairi, Russell, Nigel, Hills, Robert K and Grp, UKNCRIAML Working (2021) Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. BLOOD ADVANCES, 5 (24). pp. 5621-5625.

Collapse authors list.
Milojkovic, Dragana, Cross, Nicholas CP, Ali, Sahra, Byrne, Jenny, Campbell, Gavin, Dignan, Fiona L, Drummond, Mark, Huntly, Brian, Marshall, Scott, McMullin, Mary Frances et al (show 12 more authors) , Neelakantan, Pratap, Raghavan, Manoj, Sivakumaran, Muttuswamy, Tighe, Jane, Wandroo, Farooq, Willis, Fenella, Glen, Fiona, Fildes, Louise, Collington, Sarah J, Ryan, Jacqueline, Clark, Richard E ORCID: 0000-0002-1261-3299 and Mead, Adam J (2021) Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. BRITISH JOURNAL OF HAEMATOLOGY, 192 (1). pp. 62-74.

Cortes, Jorge E, Candoni, Anna, Clark, Richard E ORCID: 0000-0002-1261-3299, Leber, Brian, Montesinos, Pau, Vyas, Paresh, Zeidan, Amer M and Heuser, Michael (2020) Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia and Lymphoma, 61 (14). pp. 3287-3305.

Davies, Andrea, Rodriguez-Vicente, Ana Eugenia, Austin, Gemma, Loaiza, Sandra, Foroni, Letizia, Clark, Richard E ORCID: 0000-0002-1261-3299 and Pirmohamed, Munir ORCID: 0000-0002-7534-7266 (2020) Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients. Scientific reports, 10 (1). 8394-.

Collapse authors list.
Mitchell, Rebecca, Hopcroft, Lisa EM, Baquero, Pablo, Allan, Elaine K, Hewit, Kay, James, Daniel, Hamilton, Graham, Mukhopadhyay, Arunima, O'Prey, Jim, Hair, Alan et al (show 14 more authors) , Melo, Junia V, Chan, Edmond, Ryan, Kevin M, Maguer-Satta, Veronique, Druker, Brian J, Clark, Richard E ORCID: 0000-0002-1261-3299, Mitra, Subir, Herzyk, Pawel, Nicolini, Franck E, Salomoni, Paolo, Shanks, Emma, Calabretta, Bruno, Holyoake, Tessa L and Helgason, G Vignir (2018) Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 110 (5). pp. 467-478.

Clark, Richard E ORCID: 0000-0002-1261-3299 (2019) Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 14 (6). pp. 507-514.

Collapse authors list.
Clark, Richard E ORCID: 0000-0002-1261-3299, Basabrain, Ammar A, Austin, Gemma M, Holcroft, Alison K, Loaiza, Sandra, Apperley, Jane F, Law, Christopher, Scott, Laura, Parry, Alexandra D, Bonnett, Laura ORCID: 0000-0002-6981-9212 et al (show 1 more authors) and Lucas, Claire M ORCID: 0000-0001-6674-7535 (2021) Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. CANCERS, 13 (9). 2155-.

Clark, Richard E ORCID: 0000-0002-1261-3299 (2020) The chronic myeloid leukaemia story in the United Kingdom since 1960. BRITISH JOURNAL OF HAEMATOLOGY, 191 (4). pp. 521-526.

Austin, Gemma M, Knight, Katy, Bell, Joanne, Carter, Anthony, Heartin, Earnest, Watson, David, Foroni, Letizia, Christmas, Stephen E, Polydoros, Fotios and Clark, Richard E ORCID: 0000-0002-1261-3299 (2019) The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial. BRITISH JOURNAL OF HAEMATOLOGY, 185 (4). pp. 791-793.

Collapse authors list.
Ferguson, Paul, Hills, Robert K, Grech, Angela, Betteridge, Sophie, Kjeldsen, Lars, Dennis, Michael, Vyas, Paresh, Goldstone, Anthony H, Milligan, Donald, Clark, Richard E ORCID: 0000-0002-1261-3299 et al (show 2 more authors) , Russell, Nigel H and Craddock, Charles (2016) An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. HAEMATOLOGICA, 101 (11). pp. 1351-1358.

Collapse authors list.
Dennis, Mike, Burnett, Alan, Hills, Robert, Thomas, Ian, Ariti, Cono, Severinsen, Marianne T, Hemmaway, Claire, Greaves, Paul, Clark, Richard E ORCID: 0000-0002-1261-3299, Copland, Mhairi et al (show 1 more authors) and Russell, Nigel (2021) A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. BRITISH JOURNAL OF HAEMATOLOGY, 194 (2). pp. 298-308.

Collapse authors list.
Claudiani, Simone, Janssen, Jeroen JWM, Byrne, Jenny, Smith, Graeme, Blijlevens, Nicole, Raghavan, Manoj, Smith, Matthew, Clark, Richard E ORCID: 0000-0002-1261-3299, Mclain-Smith, Susan, Carter, Angela M et al (show 2 more authors) , Milojkovic, Dragana and Apperley, Jane F (2022) A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. EUROPEAN JOURNAL OF HAEMATOLOGY, 109 (1). pp. 90-99.